LABT Company Profile and Key Details

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT) closed at $2.22 USD, gaining $0.17 (8.29%) from the previous close of $2.05. The stock is currently mid-range between its 52-week high and low $1.66 and $98.20. With a market capitalization of about $3.89 million, Lakewood-Amedex Biotherapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-4.76). Key stats such as the average daily volume over the past year has been around 1.92 million shares, volume is running light vs its 52-week average. Headquartered in University Park, FL, Lakewood-Amedex Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kelvin Cooper, the company employs approximately 5 people and listed since April 23, 2026. Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.

Lakewood-Amedex Biotherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -523.08%.

Average 10-day trading volume of 938.07 thousand shares is below the 3-month average of 1.81 million, indicating normal recent market interest.

Lakewood-Amedex Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.02. This means the shares are trading below this model’s fair value.

Valuation shows Lakewood-Amedex Biotherapeutics, Inc. trading at a premium to the broader market with a P/E of -0.22. Our AI forecast model points to short-term weakness (-2.25% over two weeks), a medium-term fall (-99.1% over three months), and a longer-term loss (-98.65% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lakewood-Amedex Biotherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.25%, with price expected at $2.17 by September 25, 2026, within a range of $1.94 to $2.40 3-Month Outlook: Projected fall of -99.1%, reaching $0.02 by December 09, 2026, with a range of $0.00 to $0.17. 1-Year Outlook: Projected loss of -98.65%, with price at $0.03 by September 10, 2027, within a range of $0.00 to $0.00.

Lakewood-Amedex Biotherapeutics, Inc. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.71 suggesting the stock is closer to book value. The P/FCF stands at -1.09, also above market averages.